KariBraunWisinskiMD(She/Her)

Breast Cancer, Cancer Genetics/Cancer Risk Assessment

Professor, Chief of Hematology/Oncology and Palliative Care. Leader of Breast cancer clinical trials and collaborative translational research.

Join to view full profile

Dr. Wisinski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wisinski's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020

Summary

Dr. Kari Wisinski is a professor and breast medical oncologist at the University of Wisconsin (UW) Carbone Cancer Center and Chief of the Division of Hematology, Medical Oncology and Palliative Care, UW School of Medicine and Public Health. She is experienced in clinical research and leads the UWCCC Breast Cancer Clinical Research team and is engaged in the BigTen Cancer Research Consortium.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ColoradoResidency, Internal Medicine, 2001 - 2004
Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

WI State Medical License 2008 - 2025
IL State Medical License 2005 - 2017
CO State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Interim Chief of Hematology, Medical Oncology and Palliative Care UW School of Medicine and Public Health, 2020
Vice chair, then Chair BigTen Cancer Research Consortium Steering Committee 2018-2020
Breast Disease Oriented Team Co-Leader UWCCC, 2017-2020
Head of Solid Tumor Oncology UW Division of Hematology, Medical Oncology and Palliative Care, 2015-2020
Join now to see all

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2016 Jun 30
Active, not recruiting
Phase 2
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Start of enrollment: 2017 May 03
Terminated
Phase 2
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Start of enrollment: 2016 Sep 02
Active, not recruiting
Phase 1
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer Start of enrollment: 2017 Nov 07
Completed
Phase 2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer Start of enrollment: 2018 Dec 06
Completed
Phase 2
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Start of enrollment: 2019 Apr 17
Active, not recruiting
Phase 1, Phase 2
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Start of enrollment: 2021 Feb 12
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
Ribociclib and Bicalutamide in AR+ TNBC Start of enrollment: 2018 May 07
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphom...
Julie E Chang, Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-09
A phenocopy signature of TP53 loss predicts response to chemotherapy.
Hamza Bakhtiar, Marina N Sharifi, Kyle T Helzer, Yue Shi, Matthew L Bootsma
NPJ Precision Oncology. 2024-10-02
Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).
Alissa M Michel, Haeseung Yi, Jacquelyn Amenta, Nicole Collins, Anna Vaynrub
BMC Medical Informatics and Decision Making. 2024-09-27

Lectures

Novel Approaches for HER2-Negative Metastatic Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
Protecting Cancer Patients on High Doses of OpioidsMarch 18th, 2020
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019
Join now to see all